Navigation Links
Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
Date:10/29/2009

instruments, net of $2,005 as well as a gain on the extinguishment of a portion of the debt acquired from Indevus of $4,025.
  • To reflect the cash tax savings resulting from the Indevus acquisition and the tax effect of the pre-tax adjustments above at applicable tax rates. 
    •     Nine months Ended         Actual
     September 30, 2008      Reported
     (unaudited)               (GAAP)  Adjustments        Adjusted

    Total Revenues           $913,200            $        $913,200
    Costs and expenses:
      Cost of revenues        190,554      (21,944)  (1)   168,610
      Selling, general and
       administrative         357,775      (12,481)  (2)   345,294
      Research and
       development             82,244      (10,491)  (3)    71,753
      Impairment of other
       intangibles              8,083       (8,083)  (4)

    Operating income          274,544       52,999         327,543

      Interest income, net     (8,292)      (6,620)  (5)   (14,912)
      Other income, net          (835)                        (835)

    Income before income
     taxes                    283,671       59,619         343,290
      Income taxes            101,021       22,631   (6)   123,652

    Net income               $182,650      $36,988        $219,638

    Diluted earnings per share  $1.45           --           $1.74
    Diluted weighted
     average shares           126,012           --         126,012

    Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations:

    1. To exclude amortization of commercial intangible assets related to marketed products.
    2. To exclude separation costs of $10,459, impairment of long-lived assets of $1,482 and contract termination costs of $540.
    3. To exclude upfront and milestone payments to partners of $2,000, separation costs of $825, impairment of long lived assets of $3,115 and contract termination costs of $4,551.
    4. To exc
      '/>"/>

    SOURCE Endo Pharmaceuticals
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
    2. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
    3. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
    4. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
    5. DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units
    6. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
    7. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
    8. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
    9. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
    10. BioMarin Acquires Huxley Pharmaceuticals, Inc.
    11. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/23/2013)... PAUL, Minn. , May 23, 2013  MGC ... Corporation), a global medical technology company, today scheduled a ... second quarter of fiscal year 2013, ended April 30, ... on Thursday, May 30, 2013. The Company will report ... 2013 after the markets close on Thursday, May 30, ...
    (Date:5/23/2013)... , May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: ... biotech companies, based on intellectual property developed and ... ,s foremost medical research center, today announced ... received significant funding from the Israeli Ministry of ... (OCS) to support product development and advance clinical ...
    (Date:5/23/2013)... Anthem Blue Cross patients with HIV/AIDS may ... to obtain their medications by mail order under a ... LLC.  The lawsuit, filed in January ... mandatory mail order program announced late last year illegally ... "This settlement brings to a close a nerve-racking ...
    Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
    ... In an interview with,financial broadcaster http://www.cantos.com , GlaxoSmithKline CEO Andrew Witty ... Markets, Consumer and Vaccines. , , , ... boss also points to "an unprecedented" five new drugs in late,stage trials as a sign ... , ...
    ... ALPHARETTA, Ga. , July 21 EndoChoice, Inc. today ... in Alpharetta, Georgia .  The new 30,000 square foot corporate headquarters ... GI anatomic pathology laboratory. , , ... "We are very pleased with a seamless move into our new corporate ...
    Cached Medicine Technology:EndoChoice® Triples Facility Space to Address Growing Customer Base 2
    (Date:5/23/2013)... who eat at fast-food restaurants are consuming significantly more ... worst offenders, a new study found. "Teens underestimate ... much as 34 percent, parents of school-age children by ... much as 20 percent," study lead researcher, Dr. Jason ... Wood Johnson Foundation, which helped fund the study. ...
    (Date:5/23/2013)... when a woman harried by hot flashes says she,s ... published online in Menopause , the journal of ... objective tests that what these women say about their ... showed that hot flashes were related to memory problems, ... there was a relationship between hot flashes and what ...
    (Date:5/23/2013)... 2013 “Talk. They Hear You.” a ... parents to talk to children as young as nine ... launched today by the Substance Abuse and Mental Health ... conjunction with SAMHSA’s 2013 National Prevention Week—an annual health ... substance abuse and mental health issues. , SAMHSA’s latest ...
    (Date:5/23/2013)... May 23, 2013 Live ... contemporary services, provides the best business lead solution ... Its Call center Management solution features Free Web ... Call Limitation, Do-Not-Call Maintenance and "Automatic Transfer Retry". ... comprehensive campaign delivery and management system. , Its ...
    (Date:5/23/2013)... be tested in a clinical trial by a biomedical ... disease has failed to work with the same type ... results of a study by University of Florida researchers. ... with the Evelyn F. and William L. McKnight Brain ... of verifying promising research results before investing in clinical ...
    Breaking Medicine News(10 mins):Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2Health News:Live Lead Pros Announces The Benefits of Comprehensive Campaign Delivery and Management System 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3
    ... News) -- Scientists report that mutating a single gene produced ... finding they say could one day lead to the development ... effective drugs to treat the disorder. Mutating the shank3 ... interaction in the mice, apparently caused by impaired communication between ...
    ... By Kathleen Doheny HealthDay Reporter , SATURDAY, March ... allergy to milk as quickly as experts previously have believed. ... allergy, just over a third outgrew it within 30 months. ... that found a much higher percentage of children outgrowing the ...
    ... Jenifer Goodwin HealthDay Reporter , FRIDAY, March ... an advisory panel to the U.S. Food and Drug ... and their removal "from the marketplace would benefit public ... Scientific Advisory Committee also said that menthols, minty flavor ...
    ... March 18 (HealthDay News) -- Women in smoke-free homes ... from breast cancer, new research shows. U.S. researchers ... rates of breast cancer incidence and death. States with ... fewer breast cancer deaths, particularly among younger premenopausal women. ...
    ... FRIDAY, March 18 (HealthDay News) -- Scientists who,ve uncovered the ... to control mosquito-borne diseases such as West Nile virus and ... than 100 proteins in the male sperm of Aedes ... dengue fever -- permanently alter female mosquitoes, tendencies to feed, ...
    ... The U.S. medical system is ill-prepared to cope with the ... suggests. Specifically, too few health care providers are adequately ... the report authors indicate. The observation is outlined in ... the state of HIV health care in the United States ...
    Cached Medicine News:Health News:Outgrowing Milk Allergy May Take Some Babies Longer Than Expected 2Health News:Outgrowing Milk Allergy May Take Some Babies Longer Than Expected 3Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 2Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 3Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 4Health News:Report Highlights Shortage of HIV Care Providers in U.S. 2
    ... The Accustrip Strep A(ll) Test ... immunoassay for the rapid, qualitative ... antigen from throat swabs. The ... as an aid in the ...
    HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
    The INRatio meter is a diagnostic Point Of Care system that provides Prothrombin Time (PT) and International Normalized Ratio (INR) results using one drop of fresh capillary whole blood from a finger...
    The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
    Medicine Products: